Maa: Israel
Kieli: englanti
Lähde: Ministry of Health
PRAVASTATIN SODIUM
TEVA ISRAEL LTD
C10AA
TABLETS
PRAVASTATIN SODIUM 40 MG
PER OS
Required
TEVA ISRAEL LTD, ISRAEL
HMG COA REDUCTASE INHIBITORS
Pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . Pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *Primary prevention of coronary events: In hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - Reduce the risk of myocardial infarcton. - Reduce the risk for revascularization. - Reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *Secondary prevention of cardiovascular events: Atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior MI Pravastatin is indicated to: - Slow the progression of coronary atherosclerosis. - Reduce the risk of acute coronary events. Myocardial infarction: in patients with previous myocardial infarction and normal cholesterol levels Pravastatin is indicated to: - Reduce the risk of recurrent myocardial infarction. - Reduce the risk of undergoing myocardial revascularization procedures. - Reduce the risk of stroke and transient ischemic attack (TIA). *Hypercholesterolemia and mixed dyslipidemia: Pravastatin is indicated as an adjunct to diet to reduce elevated Total-C LDL-C and TG levels in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson type IIa and IIb).
2022-01-31
ءاودلا تابكرم ضعب نع ةماه تامولعم هابتنلإا زوتكلل لمحت مدع مهيدل نيذلا نيجلاعملا ىلع بجوتي ● نم ةليلق ةيمك ىلع يوتحت عڤيت نيتاتساﭬارﭘ صارقأ نأب لمحت مدع كيدل نأب بيبطلا لبق نم كل ليق اذإ .زوتكللا .ءاودلا اذه لوانت لبق بيبطلا عجار ،ةنيعم تايركسل صرق لكب مويدوص غلم 23 نم لقأ ىلع ءاودلا اذه يوتحي ● .مويدوصلا نم ٍ لاخ ربتعي كلذل ؟ءاودلا لامعتسإ ةيفيك )3 كيلع .بيبطلا تاميلعت بسحب ً امئاد رضحتسملا لامعتسإ بجي اميف ً اقثاو نكت مل اذإ يلديصلا نم وأ بيبطلا نم حاضيتسلإا .رضحتسملاب جلاعلا ةقيرطو يئاودلا رادقملاب قلعتي لوانتل ةفاضلإاب موحشلاب ةريقفلا ةيذغتلا ةيمهأ بيبطلا كل حرشي .جلاعلا ةرتف ةليطل ةيذغتلا هذه ةلصاوم كيلعو ،عڤيت نيتاتساﭬارﭘ بيبطلا لبق نم ناددحي جلاعلا ةقيرطو يئاودلا رادقملا :وه ةداع يدايتعلإا يئاودلا رادقملا .طقف 10-40 :مدلاب موحشلاو لورتسلوكلا بسن عافترإ ةجلاعمل ● .ءاسملا يف لضف ُ ي ،مويلاب ةرم ،غلم ،مويلاب ةرم ،غلم 40 :ةيومدلا ةيعولأاو بلقلا ضارمأ عنمل ● .ءاسملا يف لضف ُ ي .هب ىصوملا يئاودلا رادقملا زواجت زوجي لا ● جلاعلا ةرتف لامعتسإ بجي .عڤيت نيتاتساﭬارﭘ ـب جلاعلا ةرتف بيبطلا ددح ُ ي ،بيبطلا اهددح يتلا ةينمزلا ةرتفللو ،مئاد لكشب ءاودلا اذه فقوتلا زوجي لا .ةليوط ةينمز ةرتف دوصقملا ناك ولو ىتح .كسفن ءاقلت نم Lue koko asiakirja
Pravastatin Teva 20, 40mg-Tab-Notification-MW-SPC 07/2023 SUMMARY OF PRODUCT CHARACTERISTICS Pravastatin Teva 20 mg Pravastatin Teva 40 mg 1 NAME OF THE MEDICINAL PRODUCT Pravastatin Teva 20 mg Tablets Pravastatin Teva 40 mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Pravastatin Teva 20 mg- each tablet contains pravastatin sodium 20 mg. Pravastatin Teva 40 mg- each tablet contains pravastatin sodium 40 mg. Excipient(s) with known effect: Lactose monohydrate For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Tablet. Pravastatin Teva 20 mg - white to off-white, round, biconvex tablet, plain on both sides. Pravastatin Teva 40 mg - white to off white, capsules shaped tablet, scored on one side of the tablet, deossed P o the other side. The tablet can be divided into equal halves. 4 CLINICAL PARTICULARS 4.1. Therapeutic indications Pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolaemia. Pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. _Primary prevention of coronary events: _ In hypercholesterolaemic patients without clinically evident coronary heart disease pravastatin is indicated to: - Reduce the risk of myocardial infarction. - Reduce the risk for revascularization. - Reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non- cardiovascular causes. _Secondary prevention of cardiovascular events: _ Atherosclerosis: In hypercholesterolaemic patients with clinically evident coronary artery disease including prior MI Pravastatin is indicated to: - Slow the progression of coronary atherosclerosis. - Reduce the risk of acute coronary events. Pravastatin Teva 20, 40mg-Tab-Notification-MW-SPC 07/2023 Myocardial infarction: In patients with previous myocardial infarction and normal cholesterol levels Prava Lue koko asiakirja